October 16, 2017

TCS launches Connected Clinical Trials platform on its Advanced Drug Development suite

Tata Consultancy Services unveils first-of-its-kind clinical trials medication management and patient engagement platform

New York | Mumbai: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organisation, has launched Connected Clinical Trials (CCT), an innovative Software as a Service (SaaS) platform that enables pharmaceutical companies to significantly transform patient engagement in clinical trials and improve the efficiency and accountability of the clinical supply process.

CCT is part of TCS’s Advanced Drug Development (ADD) suite that offers a wide range of cloud-based clinical services, including clinical data management, metadata management, pharmacovigilance, and data analytics and insights. ADD is powered by a cognitive engine called Decision Fabric that enables automation of complex business processes. ADD leverages the best of cloud architecture and intuitive user experience design in compliance with “good clinical practice” quality guidelines (GCP) and privacy regulations.

TCS’s Connected Clinical Trials platform provides a scalable cloud solution that addresses patients’ needs through various clinical trial stages, including enrolment, treatment and follow-up stages.

CCT includes four modules:

  • CCT tracking: utilises scanners to track all medication kit transactions at the site to prevent dispensing errors, ensuring that the correct medication kit is given to the right patient at the right time.
  • CCT communication: provides patient-specific, real-time notifications, dosing instructions, tutorial videos via smart phones, enables continuous adverse event data collection, and facilitates personalised patient support in medication dosing and study procedures.
  • CCT label: employs patient-specific and easily readable all-in-one electronic drug labels in the patient's preferred language.
  • CCT adherence: enables registration and verification of individual intake via sensor-enabled medication packages (smart packages) to eliminate guesswork for medication intake, ensuring that the right pill is taken at the right time.

Janssen Research & Development, LLC collaborated with TCS to build-out TCS’s CCT platform, as part of the Janssen integrated Smart Trial and Engagement platform. 

The CCT platform has also been tested and proven in a live set-up at TCS’s state-of-the-art user experience labs with global patient and site advisory boards. This was conducted in collaboration with the Center for Information and Study on Clinical Research Participation (CISCRP), an independent non-profit organisation dedicated to educating and informing the public and patients about clinical research.

“I believe the CCT platform will help us to accurately track patient adherence to the study protocol, while also helping us to more easily and efficiently manage trial supplies at the site,” said Harpreet Isha Monga, B.Pharm, M.Pharm, PHD, Clinical Research Coordinator and Neuropsychiatric Rater at Neuro-Pain Medical Center Inc.

“TCS’s Connected Clinical Trials will enable life sciences companies to harness digital technologies to engage with patients more effectively during clinical trials and significantly improve adherence to medical dosage during those trials,” said Debashis Ghosh, president, life sciences, healthcare, government, and energy business group, TCS. “TCS’s strong domain and technology expertise makes it well positioned to offer advanced platform solutions catering to specific needs of the industry and we are excited to have Janssen as our first customer on CCT,” Mr Ghosh added.